Avastin shows guarantee for brain cancer A clinical research conducted at Henry Ford Medical center on the usage of a drug to increase the survival of individuals with common and aggressive kind of brain cancer, has yielded results which were significantly much better than expected. The randomized Stage II study centered on sufferers with glioblastoma multiforme , whose tumor had recurred after 1st – or second-range therapy. The analysis revealed that greater than a third who have been treated with Avastin alone, along with even more than half of these treated with Avastin in conjunction with the chemotherapy medication irinotecan, lived without additional progression of the condition for an interval of six months forebygging .